Your browser doesn't support javascript.
loading
Position paper from the Endocrine Task Force of the European Organisation for Research and Treatment of Cancer (EORTC) on the management and shared decision making in patients with low-risk micro papillary thyroid carcinoma.
Koot, Anna; Soares, Paula; Robenshtok, Eyal; Locati, Laura D; de la Fouchardiere, Christelle; Luster, Markus; Bongiovanni, Massimo; Hermens, Rosella; Ottevanger, Petronella; Geenen, Frans; Bartѐs, Beate; Rimmele, Harald; Durante, Cosimo; Nieveen-van Dijkum, Els; Stalmeier, Peep; Dedecjus, Marek; Netea-Maier, Romana.
Affiliation
  • Koot A; Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands; Radboud Institute for Health Sciences, Department for Health Evidence, Radboud University Medical Center, 6500 HB Nijmegen, the Netherlands. Electronic address: rosalie.k
  • Soares P; Institute for Research and Innovation in Health - i3S/Institute of Molecular Pathology and Immunology of the University of Porto-IPATIMUP, 4200-135 Porto, Portugal; Faculty of Medicine of the University of Porto, Alameda Prof. Hernani Monteiro, 4200-319 Porto, Portugal.
  • Robenshtok E; Endocrinology and Metabolism Institute, Rabin Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Israel.
  • Locati LD; Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy; Translational Oncology Unit, IRCCS Instituti Clinici Scientifici Maugeri, Pavia, Italy.
  • de la Fouchardiere C; Medical Oncology Department, Centre Léon Bérard, Lyon, France.
  • Luster M; Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany.
  • Bongiovanni M; Internal Medicine Unit, Department of Medicine, Ospedale di Circolo di Rho, ASST Rhodense, Milan, Italy.
  • Hermens R; Scientific Institute for Quality of Healthcare (IQ Healthcare), Radboud University Medical Center, 6500 HB Nijmegen, the Netherlands.
  • Ottevanger P; Department of Internal Medicine, Division of Oncology, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands.
  • Geenen F; Schildklierorganisatie Nederland (SON), the Netherlands.
  • Bartѐs B; Vivre sans Thyroïde (VST), France.
  • Rimmele H; Bundesverband Schilddrüsenkrebs - Ohne Schilddrüse Leben e.V., Germany.
  • Durante C; Department of Translational and Precision Medicine, Sapienza University of Rome, 00161 Rome, Italy.
  • Nieveen-van Dijkum E; Department of Surgery, Amsterdam UMC Location University of Amsterdam, Cancer Center Amsterdam, the Netherlands.
  • Stalmeier P; Radboud Institute for Health Sciences, Department for Health Evidence, Radboud University Medical Center, 6500 HB Nijmegen, the Netherlands.
  • Dedecjus M; Department of Endocrine Oncology and Nuclear Medicine, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Netea-Maier R; Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands.
Eur J Cancer ; 179: 98-112, 2023 01.
Article in En | MEDLINE | ID: mdl-36521335
ABSTRACT
The incidence of differentiated thyroid cancer (DTC) has been increasing worldwide, mostly, as an increase in the incidental detection of micro papillary thyroid carcinomas (microPTCs), many of which are potentially overtreated, as suggested by the unchanged mortality. Several international guidelines have suggested a less aggressive approach. More recently, it has been shown that active surveillance or minimally invasive treatments (MIT) are good alternatives for the management of these patients. In this context, patient participation in the decision-making process is paramount. The Endocrine Task Force of the European Organisation for Research and Treatment of Cancer (EORTC) has undertaken the task to establish consensus and define its position based on the scientific evidence concerning, 1) the current state of diagnostic and management options in microPTCs, including the current opinion of physicians about shared decision making (SDM), 2) the available evidence concerning patients' needs and the available decision instruments, and 3) to provide practical suggestions for implementation of SDM in this context. To improve SDM and patients' participation, knowledge gaps and research directions were highlighted.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Physicians / Thyroid Neoplasms Type of study: Etiology_studies / Guideline / Risk_factors_studies Limits: Humans Language: En Year: 2023 Type: Article

Full text: 1 Database: MEDLINE Main subject: Physicians / Thyroid Neoplasms Type of study: Etiology_studies / Guideline / Risk_factors_studies Limits: Humans Language: En Year: 2023 Type: Article